UPDATE ON MEDICINES USED IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY



The HSE reimburse three medicines for hereditary transthyretin amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy subject to a managed access protocol (MAP). The first MAP for a medicine for the treatment of hATTR with polyneuropathy was for patisiran, introduced in October 2021. This was followed by a MAP for inotersen in October 2022. A combined MAP for all medicines used in hATTR with polyneuropathy was developed with the reimbursement of vutrisiran in May 2024. The aim of this MAP is to provide patients with hATTR with polyneuropathy with access to these high-cost treatments.

Patisiran (Onpattro®) and vutrisiran (Amvuttra®) are available under hospital pricing approval and inotersen (Tegsedi®) is available under the High Tech Arrangement.

To date, the HSE have approved four prescribers under these protocols. By October 2025, 32 applications for these medicines were submitted to the HSE Medicines Management Programme. The mean age of applicants was 65 years at date of application.

October 2025

HSE Medicines Management Programme.